SCHEMBL5148552

SCHEMBL5148552

CCOC(=O)Cn1ncc(C#N)c1N

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
KDM4E B2RXH2 7/20 0.51
ALDH1A1 P00352 3/20 0.51
POLB P06746 2/20 0.51
HTT P42858 1/20 0.51
RECQL P46063 1/20 0.51
FNTA P49354 1/20 0.49
FNTB P49356 1/20 0.49
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
XDH P47989 2/20 0.43
PTGS2 P35354 1/20 0.42
F2 P00734 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581244 0.87 FNTA (0.46) SMN1; SMN2KDM4EALDH1A1POLBHTT
SCHEMBL4134200 0.82 FNTA (0.48) SMN1; SMN2KDM4EALDH1A1POLBHTT
SCHEMBL25925124 0.81 SMN1; SMN2 (0.64) SMN1; SMN2KDM4EALDH1A1POLBHTT
SCHEMBL5148661 0.79 FNTA (0.55) SMN1; SMN2KDM4EALDH1A1POLBHTT
SCHEMBL2193196 0.75 PKM (0.55) SMN1; SMN2KDM4EALDH1A1POLBHTT
SCHEMBL19208198 0.75 SMN1; SMN2 (0.57) SMN1; SMN2KDM4EALDH1A1HTTKMT2A
SCHEMBL18281328 0.73 ALDH1A1 (0.49) SMN1; SMN2KDM4EALDH1A1POLBKMT2A
SCHEMBL18755765 0.72 PKM (0.47) KDM4EALDH1A1POLBHTTRECQL
SCHEMBL2077595 0.72 PKM (0.53) SMN1; SMN2KDM4EALDH1A1POLBHTT
SCHEMBL8234335 0.72 PKM (0.55) KDM4EALDH1A1POLBHTTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179801-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-02-20 US disclosed
EP-1392704-B1 CEPHEM COMPOUNDS ASTELLAS PHARMA INC (JP) 2006-02-22 EP disclosed
US-20040248875-A1 Cephem compounds ASTELLAS PHARMA INC. (JP) 2004-12-09 US disclosed
EP-1392704-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-03 EP disclosed
WO-2002090364-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248875-A1 Cephem compounds CEP170, C1S, SLC7A1 SMN1; SMN2 1766/4885KDM4E 2903/4885ALDH1A1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.